Nuwellis, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nuwellis, Inc. (Nasdaq: NUWE) develops, manufactures, and commercializes medical devices for ultrafiltration therapy to treat fluid overload in patients with heart failure, critical illness, and related conditions; its core products include the Aquadex SmartFlow and Aquadex FlexFlow systems, comprising consoles, disposable blood circuit sets, disposable catheters, and a new U.S.-launched 24-hour circuit alongside FDA-cleared dual-lumen extended-length catheters. The company, founded in 1999 and headquartered in Eden Prairie, Minnesota, sells directly to hospitals and clinics in the United States while distributing through independent partners in countries including Austria, Brazil, Germany, India, Israel, Italy, Singapore, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom; it targets critical care, cardiology, nephrology, and pediatric segments with approximately 47 pediatric centers adopting Aquadex therapy. Recent developments encompass a May 2024 purchase agreement with a top-25 U.S. integrated delivery network for Aquadex deployment across 50 hospitals, a strategic manufacturing transition to KDI Precision Manufacturing, a $5 million capital raise in Q2 2025, expanded CMS reimbursement enabling first hospital-based outpatient therapies, new U.S. patents for fluid bag designs and blood return line clamps, participation in a $3 million NIH grant via partner Koronis Biomedical for the Vivian pediatric CRRT system, and an August 2025 non-binding letter of intent to acquire Rendiatech Ltd. for its FDA-cleared Clarity RMS real-time urine flow and acute kidney injury monitoring technologies, anticipated to close in Q4 2025.
Company News
Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical
Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript
Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin
Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer
Nuwellis Announces Next-Generation Aquadex Platform Strategy to Expand Future Critical Care Applications
Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy
Nuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in Wisconsin
Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth
Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies
Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026
Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)
Nuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® Installations
Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders
Nuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education Summit
Nuwellis Appoints Mike McCormick as Chief Executive Officer
Nuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children's Hospitals
Nuwellis Announces Closing of $6.0 Million Registered Public Offering
Nuwellis Announces Pricing of $6 Million Public Offering
Nuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex Label